BioNTech SE stock holds near USD 101 as analysts split

Published on 09/23/2026 at 11:24 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS

BioNTech SE stock reached USD 100.87 on September 22, 2026, up 2.9 percent. August revenue fell 59.5 percent year over year to USD 122.31 million.

BioNTech SE, US09075V1026, Illustration mit AI erstellt.

BioNTech SE stock (ISIN US09075V1026) reached USD 100.87 on Nasdaq on September 22, 2026, up 2.9 percent during the session. The move came as the oncology pipeline offered a counterweight to weaker operating figures and a recent target cut by BMO Capital Markets.

Analysts disagree on valuation

According to MarketBeat on September 22, 2026, BMO Capital Markets downgraded BioNTech from Outperform to Market Perform on September 8 and cut its price target from USD 128 to USD 105. The same overview reports that UBS reiterated a Buy rating on September 16, while the published consensus remained Moderate Buy with an average target of USD 126.

The target spread is material: USD 105 from BMO is USD 21 below the published USD 126 consensus, while Canaccord Genuity lowered its target from USD 142 to USD 136 on August 31, according to MarketBeat.

Revenue remains the pressure point

BioNTech reported revenue of USD 122.31 million for the quarter reported on August 4, 2026, versus analyst estimates of USD 180.18 million, according to MarketBeat. Revenue declined 59.5 percent from the same quarter a year earlier, and quarterly earnings were a loss of USD 2.53 per share compared with a consensus loss of USD 2.40.

That gap leaves the pipeline responsible for much of the valuation debate. The published company profile identifies Gotistobart among BioNTech's Phase 3 oncology programs, while the latest market coverage also points to continuing dependence on clinical progress as COVID-19 vaccine demand weakens.

Stock stays below its yearly high

Nasdaq data reported through MarketBeat showed a 52-week range of USD 79.52 to USD 124.00 and a market capitalization of USD 25.51 billion on September 22, 2026. The USD 100.87 close therefore stood USD 23.13 below the 52-week high, while trading volume reached 1,050,346 shares against an average volume of 1,100,679.

Chief Executive Ugur Sahin also sold 46,000 shares at an average USD 100.72 in a transaction dated September 22, according to MarketBeat. The filing described the transaction as part of a pre-arranged Rule 10b5-1 trading plan.

Nasdaq price remains the reference

BioNTech SE Sponsored ADRs closed at USD 100.87 on Nasdaq on September 22, 2026, up 2.9 percent on the day. The combination of a USD 126 consensus target, a USD 105 BMO target and a 59.5 percent annual revenue decline leaves clinical execution and commercial recovery as the central valuation variables.